|
Preventing Lung Cancer in Patients with Bronchial Dysplasia
Untitled Document
Name of the Trial
Phase II Study of Zileuton for the Prevention of Lung Cancer in Patients with
Bronchial Dysplasia (WSU-C-2405). See the protocol
summary 3.
Principal Investigator
Dr. Omer Kucuk, Barbara Ann Karmanos Cancer Institute.
 |
Dr. Omer Kucuk
Principal Investigator |
Why This Trial Is Important
Lung cancer is a leading cancer killer among both men and women. A condition
known as bronchial dysplasia, which is characterized by abnormal cell growth
in the bronchial tubes, may be a precursor of squamous cell lung carcinoma,
a type of non-small cell lung cancer.
Zileuton (Zyflo®) is a drug used to prevent asthma symptoms, and it is
being studied in the prevention of cancer. It belongs to the family of drugs
called lipoxygenase inhibitors. Lipoxygenases produce chemical substances called
leukotrienes that promote inflammation. Inflammation may be involved in the
development of some cancers, including lung cancer. This trial will study the
effectiveness of zileuton in eliminating bronchial dysplasia in smokers and
former smokers who are at high risk for lung cancer.
"So far there is no effective chemopreventive agent for lung cancer,"
said Dr. Kucuk. "But we know that, in animal studies, lipoxygenase inhibitors
like zileuton prevent lung cancer from developing.
"With this study, we hope to see zileuton prevent precancerous lesions
from progressing in humans, thus paving the way for larger, more conclusive
cancer prevention studies with this class of drugs," Dr. Kucuk added. "It's
a proof-of-principle study."
Contact Information
This trial is no longer open to new patients. To locate other lung cancer
clinical trials, search the NCI's database
of clinical trials 1 or call the NCI's Cancer Information Service at 1-800-4-CANCER
(1-800-422-6237). The call is toll free and completely confidential.
|
